Business
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
BROSSARD, Quebec, June 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the ...
About this update from Diagnos Inc.
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform BROSSARD, Quebec, June 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Emerging Growth Research today released a new flash report on DIAGNOS, highlighting the Company's progress toward key regulatory approvals and the growing commercialization opportunity for its CARA (Computer Assisted Retinal Analysis) artificial intelligence platform. The report notes that DIAGNOS is approaching several significant regulatory milestones that could materially expand the market opportunity for CARA, its cloud-based AI-powered software platform designed to detect retinal diseases and systemic conditions through standard fundus cameras. Key highlights from the report include: DIAGNOS is pursuing regulatory clearances with Health Canada, the U.S. Food and Drug Administration (FDA), and the Saudi Food & Drug Authority (SFDA) for its next-generation CARA platform.The Company submitted CARA to the SFDA in January 2026 and is currently responding to regulatory inquiries. Management has also indicated that a Health Canada submission was targeted for June 10, 2026, following final testing and validation.DIAGNOS completed an FDA pre-submission process in 2025, helping establish the pathway toward future 510(k) clearance in the United States.CARA has assessed more than 400,000 patients across 140 clinics in 16 countries and currently detects early signs of age-related macular degeneration (AMD) and diabetic retinopathy.In February 2026, DIAGNOS and École de Technologie Supérieure (ETS) secured more than C$1.0 million in federal funding to advance next-generation retinal AI algorithms.The Company maintains commercial relationships with major optical industry participants, including EssilorLuxottica and IRIS, which could accelerate adoption following regulatory approvals. Emerging Growth Research noted that DIAGNOS is positioned to benefit from several favorable long-term trends, including the aging global population, increasing prevalence of diabetes-related eye disease, shortages of ey...